Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults
Conditions
Interventions
FE 201836
Desmopressin
+2 more
Locations
72
United States
Achieve Clinical Research, LLC
Birmingham, Alabama, United States
Coastal Clinical Research, an AMR company
Mobile, Alabama, United States
Clinical Trials Research
Lincoln, California, United States
Tri Valley Urology Medical Group
Murrieta, California, United States
San Diego Clinical Trials
San Diego, California, United States
Advanced Rx Clinical Research Group, Inc.
Westminster, California, United States
Start Date
July 27, 2017
Primary Completion Date
October 31, 2019
Completion Date
October 31, 2019
Last Updated
March 2, 2022
NCT05562388
NCT05300308
NCT06866834
NCT05222477
NCT03883724
NCT05414279
Lead Sponsor
Ferring Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions